Stay in touch
Prime news from our network.
#read
Merck grows profitably again
Darmstadt-based science and technology group Merck has achieved a turnaround in 2024. Thanks to strong demand for medicines and semiconductor materials, adjusted EBITDA pre rose by 6.9% to EUR 6.1 billion. The fourth quarter was particularly impressive with organic sales growth of 3.8 per cent and an increase in EBITDA pre of 19.7 per cent. While the Life Science business declined over the year as a whole, it recovered in the second half of the year.
06/03/2025
For 2025, Merck expects further growth with sales of EUR 21.5 to 22.9 billion and EBITDA pre of EUR 6.1 to 6.6 billion. The dividend is to remain stable at EUR 2.20 per share. To strengthen the pharmaceutical business, the company plans to acquire the US cancer specialist Springworks Therapeutics. There will also be personnel changes: The Healthcare business sector will have a new head in Danny Bar-Zohar. In addition, Merck believes it is well positioned for the future with investments and strategic acquisitions.
Press release from "Merck" dated 6 March 2025The above texts, or parts thereof, were automatically translated from the original language text using a translation system (DeepL API).
Despite careful machine processing, translation errors cannot be ruled out.